Dalia Rotstein



Research Programs


Dr. Dalia Rotstein is an assistant professor of medicine at the University of Toronto and neurologist specialized in multiple sclerosis (MS) and other demyelinating diseases. She completed neurology residency at University of Toronto where she was co-chief resident and MS fellowship at the Brigham and Women’s Hospital/Harvard University, where she also earned a Master of Public Health degree.

Her research is focused on the epidemiology of multiple sclerosis and neuromyelitis optica spectrum disorder (NMOSD). She has a particular interest in the roles of gender, ethnicity, migration, and vitamin D in these conditions. She has performed foundational work to validate No Evidence of Disease Activity (NEDA) as an early treatment goal on MS therapy. She is the Principal Investigator for CANOPTICS, the first Canadian national prospective study to investigate adults with NMOSD, MOG Antibody Disease, and other atypical demyelinating conditions.

Dr. Rotstein founded the NMOSD Multi-Disciplinary Clinic at St. Michael’s Hospital in 2020 and the international educational program NIRVE, the Neurology International Residents Videoconferencing Exchange, in 2009. She now serves as the faculty mentor for NIRVE and enjoys mentoring students, residents and fellows. She is an associate editor for the journal Frontiers in Neurology.

Recent Publications

  1. Solomon, JM, Paul, F, Chien, C, Oh, J, Rotstein, DL. A window into the future? MRI for evaluation of neuromyelitis optica spectrum disorder throughout the disease course. Ther Adv Neurol Disord. 2021;14 :17562864211014389. doi: 10.1177/17562864211014389. PubMed PMID:34035837 PubMed Central PMC8111516.
  2. Rotstein, DL, Yeh, EA. Could wider social networks prevent disability in MS and other neurologic disorders?. Neurology. 2020;95 (11):463-464. doi: 10.1212/WNL.0000000000010452. PubMed PMID:32769138 .
  3. Rotstein, DL, Marrie, RA, Tu, K, Schultz, SE, Fung, K, Maxwell, CJ et al.. Health service utilization in immigrants with multiple sclerosis. PLoS One. 2020;15 (7):e0234876. doi: 10.1371/journal.pone.0234876. PubMed PMID:32645017 PubMed Central PMC7347150.
  4. Rotstein, DL, Sawicka, K, Bharatha, A, Montalban, X, Lipton, JH. CNS demyelination after initiating the tyrosine kinase inhibitor imatinib: A report of two cases. Mult Scler. 2020;26 (9):1121-1124. doi: 10.1177/1352458519892914. PubMed PMID:31845621 .
  5. Rotstein, DL, Marrie, RA, Maxwell, C, Gandhi, S, Schultz, SE, Fung, K et al.. MS risk in immigrants in the McDonald era: A population-based study in Ontario, Canada. Neurology. 2019;93 (24):e2203-e2215. doi: 10.1212/WNL.0000000000008611. PubMed PMID:31690681 PubMed Central PMC6937488.
  6. Rotstein, DL. Disease-modifying therapies should be stopped in NMOSD patients in remission - No. Mult Scler. 2019;25 (9):1218-1220. doi: 10.1177/1352458519832249. PubMed PMID:30900934 .
  7. Rotstein, DL, Cortese, M, Fung, TT, Chitnis, T, Ascherio, A, Munger, KL et al.. Diet quality and risk of multiple sclerosis in two cohorts of US women. Mult Scler. 2019;25 (13):1773-1780. doi: 10.1177/1352458518807061. PubMed PMID:30351179 PubMed Central PMC6478561.
  8. Rotstein, DL, Bharatha, A, Selchen, D. Severe aseptic temporal lobe encephalitis on fingolimod. Mult Scler Relat Disord. 2018;23 :4-6. doi: 10.1016/j.msard.2018.04.008. PubMed PMID:29689473 .
  9. Rotstein, DL, Chen, H, Wilton, AS, Kwong, JC, Marrie, RA, Gozdyra, P et al.. Temporal trends in multiple sclerosis prevalence and incidence in a large population. Neurology. 2018;90 (16):e1435-e1441. doi: 10.1212/WNL.0000000000005331. PubMed PMID:29549225 .
  10. Rotstein, DL. A protean disease: The phenotypic range of neuromyelitis optica spectrum disorder. Mult Scler. 2018;24 (5):688-689. doi: 10.1177/1352458517726867. PubMed PMID:28814129 .
Search PubMed

Affiliations & Other Activities

  • Neurologist, Multiple Sclerosis Clinic, St. Michael’s Hospital
  • Assistant Professor, Department of Medicine, Division of Neurology, University of Toronto.